Lu Peng sold $602K of PHVS

Lu Peng (President) sold 15,000 shares of Pharvaris N.V. (PHVS) at $40.13 ($0.60M total) on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lu Peng
Published Sep 15, 2026, 6:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosed sale is modest and likely already priced in; traders should focus on larger catalysts.

02

Market read

Primary insider sale with limited material impact; low trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 5/10Timing: filing date 2026-09-15

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale is pre‑arranged and often non‑informative.

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

President Lu Peng sold 15,000 shares for $602K via a 10b5-1 plan, reducing his holdings to 65,179 shares.

Expected impact

minor downward pressure or flat price action

Evidence & confidence

The sale amount is modest relative to market cap and follows a pre‑arranged plan, limiting informational value.

Market effects

No broader sector impact; insider sale is company‑specific.

Limited to US biotech investors; no regional ripple.

Minimal global relevance.

Counterpoint

The sale could be routine and unrelated to fundamentals; investors may ignore it.

Key entities

  • Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Lu Peng

    President of Pharvaris, reporting a sale of 15,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.